CTOs on the Move

Simonmed Imaging

www.simonmed.com

 
SimonMed Imaging is one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States. Our practice consists of over 200 highly-experienced subspecialty-trained radiologists, and we operate across 9 states with over 150 accredited facilities that are ACR-RADSITE certified with certified technologists and equipment. We specialize in using the newest diagnostic imaging technologies and bringing them to the community in an affordable and accessible way. Our logo See Tomorrow Today recognizes that new technology can help provide a more accurate diagnosis but needs to be readily available and affordable.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.simonmed.com
  • 6900 E Camelback Road Suite 700
    Scottsdale, AZ USA 85251
  • Phone: 866.614.8555

Executives

Name Title Contact Details
Sebastian Bretschneider
Chief Operating Officer Profile
Chris Schweigert
Chief Information Security Officer Profile
Duleep Wikramanayake
Chief Information Officer Profile
Steven Murray
Chief Information Security Officer Profile

Similar Companies

Pleiad

Pleiad is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMR 4 DOCTORS

EMR 4 DOCTORS is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tenaxis Medical

Tenaxis Medical is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Health and Wellness

Thank you for visiting our page. We want everyone to enjoy on our Wall so here are a few things that youll need to know in order to post. We reserve the right to delete a comment or post containing any of the following (NOTE: We may also block the ...

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.